Grzegorz S. Nowakowski, MD

Grzegorz S. Nowakowski, MD, discusses the potential implications of the TakeAim Lymphoma trial of emavusertib plus ibrutinib in patients with PCNSL.

Grzegorz S. Nowakowski, MD, discusses the clinical implications of the FDA approval of third-line epcoritamab for relapsed/refractory follicular lymphoma.

Grzegorz S. Nowakowski, MD, discusses unmet needs that remain to be addressed in patients with relapsed/refractory follicular lymphoma.

Grzegorz S. Nowakowski, MD, discusses the treatment landscape for DLBCL and the need for novel therapeutic approaches in the second-line setting.

Grzegorz S. Nowakowski, MD, discusses results from the EPCORE NHL-1 trial of third-line epcoritamab in relapsed/refractory follicular lymphoma.

Grzegorz S. Nowakowski, MD, discusses the significance of the FDA approval of epcoritamab in relapsed/refractory follicular lymphoma.

A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.

A panel of experts discuss how to sequence BTK inhibitors and CAR T-cell therapies in patients with MCL.

Experts on mantle cell lymphoma discuss third-line treatment options available for patients.

Experts on mantle cell lymphoma discuss second-line treatment options available for patients.

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline MCL.

Experts on mantle cell lymphoma discuss first-line treatment options available for patients.

Laurie Sehn, MD, and Bijal Shah, MD, discuss remaining unmet needs for patients with relapsed/refractory FL.

Peter Martin, MD, discusses how to sequence bispecific T-cell engagers and CAR T-cell therapies in the third-line and beyond setting for FL.

Jennifer Crombie, MD, discusses how to choose CAR T-cells as third-line and beyond therapy for FL.

A panel of experts discuss how to choose bispecific T-cell engagers as third-line and beyond therapy for FL.

Laurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.

Grzegorz S. Nowakowski, MD, discusses data from the phase 1/2 TakeAim Lymphoma trial of emavusertib plus ibrutinib in patients with hematologic malignancies.

Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.

Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.

Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.

Experts on follicular lymphoma discuss second-line treatment options available for patients.

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline FL.

Experts on follicular lymphoma discuss first-line treatment options available for patients.

Shared excitement for bispecific antibodies and other promising novel therapies in the treatment of patients with DLBCL.

A look at exciting investigational agents and clinical trials for patients with relapsed/refractory diffuse large B-cell lymphoma.

The panelists share their approach to the treatment and work-up of patients who require salvage therapy.

Experts in lymphoma take part in a discussion on supportive care for patients who receive CAR T-cell therapy.

Subject matter experts in lymphoma reflect on chimeric antigen receptor T-cell therapy clinical trial design.

Frederick Locke, MD, provides an in-depth look at data from 3 clinical trials investigating chimeric antigen receptor T-cell therapy in the second-line treatment of diffuse large B-cell lymphoma.